Skip to main content

Advertisement

Table 1 Descriptive characteristics and bloodborne data of pre-diabetic subjects before and after an eight week intervention of ALCA or placebo

From: Effect of oral acetyl L-carnitine arginate on resting and postprandial blood biomarkers in pre-diabetics

Variable Pre Intervention ALCA Post Intervention ALCA Pre Intervention Placebo Post Intervention Placebo
Age (yrs) 31 ± 3 31 ± 3 35 ± 3 35 ± 3
Height (cm) 172 ± 3 172 ± 3 169 ± 3 169 ± 3
Weight (kg) 85 ± 4 83 ± 5 91 ± 5 90 ± 4
BMI (kg·m-2) 28.5 ± 1.9 27.8 ± 1.7 31.7 ± 2.1 32.6 ± 2.4
Body Fat (%) 28 ± 2 26 ± 3 28 ± 2 27 ± 2
Waist (cm) 94 ± 4 92 ± 4 101 ± 5 100 ± 5
Hip (cm) 109 ± 4 106 ± 4 113 ± 5 111 ± 6
Waist:Hip 0.87 ± 0.05 0.87 ± 0.03 0.89 ± 0.04 0.90 ± 0.05
Resting HR (bpm) 73 ± 2 71 ± 2 73 ± 2 72 ± 3
Resting SBP (mmHg) 123 ± 1 121 ± 1 119 ± 1 118 ± 2
Resting DBP (mmHg) 79 ± 1 78 ± 1 80 ± 1 80 ± 1
Glucose (mg·dL-1) 109 ± 5 103 ± 5 112 ± 6 111 ± 5
HbA1c (%) 6.6 ± 1.9 6.2 ± 2.2 6.7 ± 1.8 6.6 ± 2.2
Insulin (μU·mL-1) 12.1 ± 1.8 11.4 ± 2.1 12.4 ± 1.9 12.7 ± 2.0
HOMA-IR 3.3 ± 1.3 2.9 ± 1.2 3.4 ± 1.4 3.5 ± 1.6
Total Cholesterol (mg·dL-1) 195 ± 13 192 ± 14 184 ± 14 179 ± 15
HDL-C (mg·dL-1) 51 ± 7 48 ± 6 47 ± 4 50 ± 5
LDL-C (mg·dL-1) 127 ± 13 132 ± 11 123 ± 8 117 ± 10
CRP (ng·mL-1) 1432 ± 342 1389 ± 328 1652 ± 408 1738 ± 425
  1. Data are mean ± SEM.
  2. No statistically significant differences noted (p > 0.05).